Upgrading PAS-X is no longer optional it’s a critical step in ensuring compliance, operational resilience, and digital readiness in modern pharmaceutical manufacturing.
As PAS-X 3.1 and 3.2 approach end-of-support, manufacturers face mounting risks: outdated system functionality, increasing validation burdens, cybersecurity vulnerabilities, and costly production disruptions. At the same time, new PAS-X versions offer powerful opportunities to streamline processes, modernize infrastructure, and strengthen data integrity.
This white paper explores:
The business and regulatory drivers pushing life sciences companies to upgrade now
How to build a realistic, risk-aware business case for your migration
A proven, step-by-step strategy for PAS-X upgrades from impact assessment to execution
Common pain points such as validation overload, customizations, and data migration and how to avoid them
How AI-assisted recipe migration reduces manual effort and protects critical process knowledge
Key considerations when choosing between Big Bang and Line-by-Line upgrade approaches
Whether you’re early in planning or preparing for execution, this white paper provides the clarity and structure needed to navigate the complexity of PAS-X migrations.
Download the white paper to learn how a modern PAS-X platform can drive compliance, operational excellence, and long-term manufacturing agility.
Fill out the form and get access to our white paper
